Published in Cancer Weekly, October 9th, 1995
The purpose of the study is to determine whether TretinoinLF can induce and sustain remission in patients with acute promyelocytic leukemia (APL) who have relapsed following prior therapy.
"We are particularly enthusiastic about this trial because our Phase I human study demonstrated that we can safely deliver high levels of the drug that are maintained in the bloodstream for extended periods," said Dr. Elihu Estey, Professor of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (1995-10-09)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.